GLPwatch
Papers (10376)
Page 87 of 173, ranked by citation count.
- Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
- Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity.
- Liraglutide protects β-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats.
- Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
- The comparison of three different molecular imaging methods in localization and grading of insulinoma.
- Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.
- Evaluating the safety profile of semaglutide: an updated meta-analysis.
- Cardiovascular Effects of Liraglutide.
- Glucagon-like peptide-1 receptors agonists (GLP1 RA).
- Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.
- Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.
- Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line.
- Exendin-4 decreases ghrelin levels through mTOR signaling.
- Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
- Semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease.
- Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
- Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
- An unusual case of a generalised cutaneous drug reaction to liraglutide.
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
- Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide.
- Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression.
- The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.
- The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.
- Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.
- [Regulatory effect of liraglutide on the expression of eNOS in the corpus cavernosum of diabetic rats].
- The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide.
- Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
- Dulaglutide for the treatment of type 2 diabetes.
- Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
- GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.
- Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.
- Exendin-4 attenuates brain death-induced liver damage in the rat.
- Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.
- A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
- Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
- Change in HbA<sub>1c</sub> Across the Baseline HbA<sub>1c</sub> Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.
- [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
- Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
- Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.
- Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.
- Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.
- Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
- No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.
- Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus.
- Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis.
- The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
- Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.
- PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats.
- pH-temperature Responsive Hydrogel-Mediated Delivery of Exendin-4 Encapsulated Chitosan Nanospheres for Sustained Therapeutic Efficacy in Type 2 Diabetes Mellitus.
- Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.
- Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
- Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.
- SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.
- Semaglutide and effective weight control.
- Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
- Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.
- Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
- Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective.
- Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.
- Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.